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Dibenz-[1,4] diazepine-1-ones constitute an important class of
bioactive compounds due to their central nervous system
depressing effect. They are widely prescribed as psychotropic
drugs (Ator and Grifﬁth, 1997; Nabih et al., 2003). Dib-
enzodiazepine derivatives are one of the most known atypical
neuroleptic agents which possess antimuscarinic, antiseroton-ergic, sedative and weak antidopaminergic properties (Liegeois
et al., 1993, 1995). Benzodiazepine derivatives bind to the gam-
ma subunit of the c-aminobutyric acid (GABAA) receptor.
Their binding causes an allosteric modiﬁcation of the receptor
activity, which leads to an increase in the chloride conductance
and inhibition of the action potential (Falco et al., 2005; Nash
and Nutt, 2004). The GABAA receptors are pentameric ligand
gated chloride ion channels assembled from at least 16 sub-
units from seven different classes (a1–6, b1–3, c1–3, d, e, G,
and h) (Sieghart, 2006; Johnston, 2005; Olsen and Sieghart,
2009). The benzodiazepine-binding site (BZDR) is believed
to be located at an interface between a and c subunit and li-
gands of the receptor are believed to mediate their pharmaco-
logical effect predominately through interactions at the a1bxc2,
a2bxc2, a3bxc2, and a5bxc2 subtype assemblies. Studies
with transgenic mice and subtype selective compounds clearly
Scheme 1 Synthesis of Dibenz [1, 4]-diazepine-1-one catalyzed by Oxalic acid in water.
Scheme 2 Synthesis of 4-chloro-5-(3,4-dichlorophenoxy)benzene-1,2-diamine (Campos et al., 2002).
Table 1 The effect of catalyst on model reaction 4aa.
Entry Catalystb Time (min) Yield (%)c
1. No catalyst 240 40
2. CH3COOH 120 76
3. Sulfamic acid 130 80
4. Oxalic acid 120 94
a Reaction condition diamine (1) (1.0 mmol), substituted alde-
hyde (2) (1.0 mmol), water (5 mL), 1,3diketone (3) (1.0 mmol) and
oxalic acid (40 mol%) reﬂuxed at 100 C.
b 40 mol% Of catalyst were used for standardization of catalyst.
c Isolated yields of two runs.
Table 2 Effect of concentration of oxalic acid on model
reaction 4aa.
Entry mol% Time (min) Yield (%)b
1. 10 135 88
2. 20 135 89
3. 30 120 91
4. 40 120 94
5. 50 120 94
a Reaction condition diamine (1) (1.0 mmol), substituted alde-
hyde (2) (1.0 mmol), water (5 mL), 1,3diketone (3) (1.0 mmol) and
oxalic acid (40 mol%) reﬂuxed at 100 C.
b Isolated yields of two runs.
Table 3 Screening of solvent for model reaction 4aa.
Entry Solvent Time (min) Yield (%)b
1. Acetonitrile 180 60
2. Iso-propylalcohol 180 65
3. Methanol 120 90
4. Ethanol 120 94
5. Ethanol–Water (50%) 120 94
6. Water 120 94
a Reaction condition diamine (1) (1.0 mmol), substituted alde-
hyde (2) (1.0 mmol), water (5 mL), 1,3 diketone (3) (1.0 mmol) and
oxalic acid (40 mol%) reﬂuxed at 100 C.
b Isolated yields of two runs.
Green synthesis and anxiolytic activity of some new dibenz-[1,4] diazepine-1-one analogues S1357suggest that GABAA receptors with different subtype compo-
sition are associated with different physiological effects,
a1-containing receptors mediate sedative and anterograde
amnesic effects, a2, and a3 containing receptors are involved
in the anxiolytic activity, while a5 containing receptors might
be associated with cognition and memory (Rudolph et al.,
1999, 2001).
The most common approaches for the preparation of di-
benz-[1,4] diazepine-1-one involve internal mannich reaction
(Tonkikh et al., 2004), cyclization, condensation (Wang
et al., 2011), and C aryl–N bond construction, accomplished
by a palladium-catalyzed intramolecular N-arylation (Susana
et al., 2011). However, most of these involve multi-step proce-
dures and have signiﬁcant drawbacks such as long reaction
times, low yields of the products, harsh reaction conditions,
difﬁcult work-up and the use of expensive and environmentally
toxic catalysts, reagents or media. The development of simple
and efﬁcient methods for the synthesis of dibenz-[1,4] diaze-
pine-1-ones is therefore strongly desirable.Based on the above facts and due to our interest in estab-
lishing the synthetic strategies for new biologically active het-
erocycles (Sangshetti et al., 2009, 2011a,b; Sangshetti and
Shinde, 2010a,b, 2011), we have reported a facile methodology
Table 4 Synthesis of Dibenz [1,4]-diazepine-1-one derivatives using oxalic acid as catalyst in watera.
Entry Diamine (1) Aldehyde (2) 1,3 diketone (3) Time (min) Yield (%)b Melting Point in C*
4a 120 94 250–253
4b 120 92 273–275
4c 130 93 268–270
4d 130 90 258–260
4e 120 94 264–266
4f 125 92 275–277
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Table 4 (continued)
4g 120 93 263–264
4h 130 92 258–216
4i 120 91 280–281
4j 120 89 274–276
4k 120 92 268–270
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S1360 J.N. Sangshetti et al.for the synthesis of some new dibenz-[1,4] diazepine-1-one
derivatives by three component reaction of diamine, substi-
tuted aldehydes and 1,3-diketones by using oxalic acid as a cat-
alyst in water. The newly synthesized compounds have further
been tested for the anxiolytic activity.
2. Result and discussion
2.1. Chemistry
All dibenz-[1,4] diazepine-1-one derivatives prepared in this
study are new compounds. Dibenz-[1,4] diazepine-1-one scaf-
fold (4a–4l) was synthesized by using synthetic route outlined
in Scheme 1 by cyclocondensation of diamine (1) 1,3-diketone
(2) and aromatic aldehydes (3) in the presence of oxalic acid in
good yield. 4-chloro-5-(3,4-dichlorophenoxy) benzene-1,2-dia-
mine (1) is prepared by using 4,5-dichloro-2-nitro aniline (a)
and 2,3-dichlorophenol (b) giving an intermediate nitro com-
pound. The nitro compound on further reduction with SnCl2
gives 4-chloro-5-(3,4-dichlorophenoxy) benzene-1,2-diamine
(1) as shown in Scheme 2 (Campos et al., 2002). Optimization
of the reaction has been carried out using different catalyst
considering a model reaction 4a. The results are presented in
Table 1. From the data it is observed that use of oxalic acid
is more favorable. The reaction has also been optimized for
concentration of oxalic acid. Use of 40 mol% oxalic acid is
suitable for maximum yield (Table 2). Reaction has also been
tried with different solvent; the effect of different solvent on
yield of the reaction was evaluated. The results are summarized
in Table 3. The yield and physical constant data of all the new-
ly synthesized compounds have been represented in Table 4.
3. Pharmacology
3.1. Anxiolytic activity
Anxiety behavior was induced and assessed in albino mice
using an elevated plus maze (EPM) apparatus (Sheibania
et al., 2011). The animals were randomly assigned to different
experimental and control groups. Grouped mice were brought
into the testing room and allowed to acclimatize to the new
environment for 30 min. The experiments were carried out in
a dimly-lit room (44-lux). A trained observer scored the
parameters. After each trial, the maze was cleaned with etha-
nol solution (10% v/v). The mice were placed in the center
of EPM and were allowed to explore EPM for 5 min. Diaze-
pam (DZP) was used as the reference standard. Animals were
given the test compound 4a–4l (2 mg/kg, i. p.), DZP (2 mg/kg,
i.p.) and vehicle (Tween 20, 5%, i.p.). The anxiolytic activity
was evaluated through the number of entries and the average
time spent in seconds in the arms of EPM during the test.
These were used to calculate percent open arm entry (%
OAE, [open arm entries/(open + closed arm entries)] · 100),
percent closed arm entry (% OCE, [close arm entries/
(open + closed arm entries)] · 100), percent time spent in open
arm (% TOA, (open arm time/300) · 100), percent time spent
in close arm (% TCA, (close arm time/300) · 100).
The effect of compounds (4a–4l), DZP and vehicle on the
time spent and number of entries into the arms of EPM are
shown in Table 5 and Figs. 1 and 2 Increase in the OAE and
percent TOA indicates the anti-anxiety activity. All the
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Table 5 Effect of Dibenz [1,4]-diazepine-1-one derivative (4a–4l) on the relative parameters in the EPM for measurement of anxiolytic activity.
DV VEH DZP 4a 4b 4 4d 4e 4f 4 g 4 h 4i 4j 4 k 4 l
OAE 3.3 ± 0.6 10.3 ± 1.3* 7.6 ± 1.6* 8.1 ± 0.5* 8.6 ± 0.6* 7.6 ± 1.8 * 7.5 ± 0.9* 6.8 ± 0.4* 10.6 ± 0.4* 12.0 ± 0.5* 6.3 ± 0.7 ns 5.3 ± 0.4 ns 13.0 ± 0.5* 9.0 ± 0.3*
CAE 13.0 ± 0.6 5.5 ± 0.9* 6.0 ± 1.2* 5.3 ± 0.8* 7.6 ± 0.8* 9.5 ± 1.9* 8.0 ± 1.0* 6.0 ± 0.0* 7.1 ± 0.4* 6.1 ± 0.4* 6.3 ± 0.6* 4.1 ± 0.3* 7.5 ± 0.4* 7.8 ± 0.3*
TOA 17 ± 2.0 120.0 ± 5.1* 129.8 ± 1.5* 151.5 ± 9.8* 1 6.5 ± 5.3* 105.5 ± 1.3* 120.0 ± 8.6* 76.5 ± 2.3* 80.8 ± 1.2* 88.5 ± 2.1* 39.3 ± 1.4ns 18.0 ± 1.0ns 74.0 ± 1.9* 100.7 ± 1.2*
TCA 223.0 ± 1.1 95.0 ± 1.6* 99.3 ± 2.1* 68.6 ± 8.2* 1 0.5 ± 1.3* 67.0 ± 8.2* 102.8 ± 3.6* 145.2 ± 1.6* 167.0 ± 2.6* 157.5 ± 2.1* 209.8 ± 4.3ns 233.2 ± 1.6ns 170.5 ± 1.3* 126.5 ± 5.0*
% OAE 19.3 ± 2.7 65.0 ± 4.4* 56.9 ± 4.7* 61.8 ± 3.6* 3.4 ± 1.1* 45.7 ± 8.1* 48.3 ± 0.7* 52.8 ± 1.8* 59.7 ± 2.2* 65.9 ± 2.7* 49.9 ± 0.8* 56.0 ± 2.1* 63.3 ± 1.5* 53.4 ± 0.4*
% CAE 80.6 ± 2.7 34.9 ± 4.4* 42.8 ± 4.6* 38.0 ± 3.6* 6.4 ± 1.1* 54.2 ± 8.1* 51.6 ± 0.7* 47.0 ± 1.8* 40.1 ± 2.2* 33.9 ± 2.7* 49.6 ± 1.1* 43.9 ± 2.1* 36.5 ± 1.5* 46.4 ± 0.4*
% TOA 5.6 ± 0.6 40.1 ± 1.7* 43.2 ± 0.5* 50.4 ± 3.2* 5.4 ± 1.7* 35.1 ± 0.4* 40 ± 2.8* 25.4 ± 0.7* 26.9 ± 0.4* 29.4 ± 0.7* 13 ± 0.5* 5.9 ± 0.3ns 24.6 ± 0.6* 33.5 ± 0.3*
% TCA 74.3 ± 4.7 31.6 ± 3.5* 33 ± 0.7* 22.8 ± 2.7* 3.4 ± 0.4* 22.3 ± 2.7* 34.2 ± 1.2* 48.3 ± 0.5* 55.6 ± 0.8* 52.4 ± 0.7* 69.9 ± 1.4* 76.8 ± 4.0ns 56.8 ± 0.4* 42.1 ± 1.7*
Data represent mean values ± SEM; n= 6. DV – Dependent V riable, VEH- Vehicle Tween 20 (5%), DZP –Diazepam,OAE – Open Arm Entry, CAE – Closed Arm Entry, TE – Total EntryTOA
– Time in Open Arm, TCA- Time in Closed Arm, TT – Total Ti e,%OAE –%Open Arm Entry, %CAE –%Closed Arm Entry, %TOA –%Time in Open Arm, %TCA –%Time in Closed Arm.
ns Non signiﬁcant.
* The mean difference is signiﬁcant at the 0.05 level.
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S1362 J.N. Sangshetti et al.except in compound with 2,4dimethoxy aromatic substitution
(4k). Analogues synthesized from o-phenylene diamine (4a, 4l)
are less potent as compared to analogues synthesized from 4-
chloro-5-(3,4-dichlorophenoxy)benzene-1,2-diamine (4b–4k).
5. Conclusion
A new series of dibenz[1,4]-diazepine-1-one has been synthe-
sized by a one pot green method. The reaction has been com-
pleted with good to excellent yield in short reaction time.
Newly synthesized compounds were subjected to anxiolytic
activity. Compounds (4g), (4h) and (4k) are the most active
compounds showing signiﬁcant anxiolytic activity. The high-
lighting advantages of this method are a catalytic process for
the synthesis of dibenz[1,4]-diazepine-1-one catalyzed by oxalic
acid as catalyst using water as a media by one pot three com-
ponent condensation of aromatic aldehydes, 1,3-diketones,
diamines. Water is used as a reaction medium which is eco-
friendly, inexpensive and abundantly available. Other advanta-
ges of this method are good yield, short reaction time, easy
work-up, simplicity in operation, use of green solvents, mild
reaction conditions.
6. Experimental
The substituted aldehydes, o-phenylene diamine, 1,3-diketone
and oxalic acid were commercially available. Melting points
were recorded on Thiele’s tube apparatus and are uncorrected.
1H NMR spectra were recorded on a 400 MHz BRUKER
spectrometer and 13C NMR spectra were recorded on a
100 MHz BRUKER spectrometer and are reported as parts
per million (ppm) downﬁeld from a tetramethylsilane internal
standard. The following abbreviations are used, singlet (s),
doublet (d), triplet (t), quartet (q), multiplet (m) and broad
(br). Mass spectra were taken with Micro mass-QUATTRO-
II of WATER mass spectrometer.
6.1. General procedure for the synthesis of Dibenz[1,4]-
diazepine-1-one derivatives
In a 50 ml reaction ﬂask, the diamine (1 mmol), (1) 1,3-dike-
tone (1mmole) (2), oxalic acid (40 mol%), and water (5 ml)
were mixed and then stirred for 30 min. Subsequently aldehyde
(3) (1 mmol) was added to the reaction mixture, and the mix-
ture was reﬂuxed for 120 min. Upon completion monitored by
TLC (Ethylacetate 30%-n-Hexane 70%), the reaction mixture
was cooled to room temperature, ﬁltered to give the crude
product which was further recrystallized using ethanol to give
pure product.
6.2. Spectral characterization
6.2.1. 11-(4-chlorophenyl)-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4a)
Pale Yellow Solid, ES-MS m/z (%): 325 (M+H) 1HNMR
(400 MHz, CDCl3); 7.85–7.34 (m, 4H), 6.85–6.51(m, 4H),
6.00(d, 1H), 4.51(s, 1H), 4.51(s, 1H), 3.94 (t, 2H), 2.96(t,
2H), 1.97(m, 2H) 13C NMR (100 MHz, CDCl3); 199.9,
144.4, 136.5, 134.2, 132.3, 128.6, 118.9, 119.5, 105.1, 53.3,
36.8, 27. 3, 25.6.6.2.2. 8-chloro-11-(4-chlorophenyl)-7-(3,4-dichlorophenoxy)-
2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one
(4b)
White Solid, ES-MS m/z (%): 521(M+H) 1H NMR
(400 MHz, CDCl3); 7.98–7.18(m, 3H), 7.37–7.34(m, 4H),
6.49–6.05(m, 2H), 5.50(d, 1H), 4.5(s, 1H), 4.4 (s, 1H), 3.98(t,
2H), 2.96(t, 2H), 1.97(m, 2H) 13C NMR (100 MHz, CDCl3);
195.9, 155.5, 148.1, 135.3, 133.1, 126.5, 119.6, 129.0, 141.4,
119.7, 117.4, 126.3, 131.0, 128.6, 104.8, 117.0, 128.6, 127.1,
53.3, 36.0, 25.1.
6.2.3. 8-chloro-7-(3,4-dichlorophenoxy)-11-phenyl-
2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one
(4c)
Yellowish brown Solid, ES-MS m/z (%): 485 (M+H) 1H
NMR (400 MHz, CDCl3); 7.89–7.38 (m,3H), 7.83–7.23
(m,5H), 6.49–6.05 (m,2H), 5.8 (d,1H), 4.4 (s,1H), 4.7 (s,1H),
3.94 (t,2H), 3.96 (t,2H), 1.87 (m,2H) 13C NMR (100 MHz,
CDCl3); 196.5, 153.5, 130.2, 128.1, 126.5, 129.0, 123.3, 131.7,
119.7, 114.4, 131.0, 115.8, 107.8, 104.9, 128.9, 126.7, 36.0,
27.3, 53.3, 24.5.
6.2.4. 8-chloro-11-(2-chlorophenyl)-7-(3,4-dichlorophenoxy)-
2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one
(4d)
Off-white Solid, ES-MS m/z (%): 521 (M+H) 1H NMR
(400 MHz, CDCl3); 8.71–7,58 (m, 3H), 7.65–7.39 (m, 4H),
6.49–6.13 (m, 2H), 5.56 (d, 1H), 4.5 (s, 1H), 4.34 (s, 1H),
3.94 (t, 2H), 2.96 (t, 2H), 2.67 (m, 2H) 13C NMR (100 MHz,
CDCl3); 188.9, 154.5, 141.1, 133.1, 131.2, 129.0, 126.2, 142.8,
119.7, 128.6, 114.4, 120.3, 36.0, 27.3.
6.2.5. 8-chloro-7-(3,4-dichlorophenoxy)-11-(2,6-
dichlorophenyl)-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4e)
Pale Yellow Solid, ES-MS m/z (%): 554 (M+H) 1H NMR
(400 MHz, CDCl3); 8.89–7.45(m, 4H), 7.53–7.25 (m, 3H),
6.49–6.05 (m, 2H), 5.00 (d, 1H), 4.0 (s, 1H), 4.0 (s, 1H), 2.94
(t, 2H), 1.96 (t, 2H), 1.67 (m, 2H) 13C NMR (100 MHz,
CDCl3); 198.9, 152.5, 143.2, 133.6, 126.3, 124.7, 116.6, 109.8,
101.1, 53.6, 26.9, 27.9, 26.3.
6.2.6. 8-chloro-7-(3,4-dichlorophenoxy)-11-(3,4-
dihydroxyphenyl)-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4f)
Yellowish brown Solid, ES-MS m/z (%): 517 (M+H) 1H
NMR (400 MHz, CDCl3); 7.71–7.48 (m,3H),7.60–6.62
(m,3H), 6.49–6.25 (m,2H), 5.38 (s,1H), 5.20 (s,1H), 5.00
(d,1H), 4.4 (s,1H), 4.7 (s,1H), 2.98 (t,2H), 1.96 (t,2H), 1.97
(m,2H) 13CNMR (100 MHz, CDCl3); 192.9, 153.5, 145.5,
140.1, 137.3, 133.1, 129.7, 126.5, 121.7, 120.0, 117.9, 115.8,
114.9, 111.0, 109.5, 101.1, 53.0, 36.9, 27.9, 24.5.
6.2.7. 8-chloro-7-(3,4-dichlorophenoxy)-11-(2,4-
dimethoxyphenyl)-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4g)
Yellow Solid, ES-MS m/z (%): 545 (M+H) 1H NMR
(400 MHz, CDCl3); 8 .71–7.28 (m,3H), 7.61–7.45 (m,3H),
6.49–6.05 (m,2H), 5.2 (d,1H), 4.2 (s,1H), 4.6 (s,1H), 3.98
(s,3H), 3.93 (s, 3H), 3.94 (t, 2H), 2.96 (t,2H), 1.67 (m,2H)
Green synthesis and anxiolytic activity of some new dibenz-[1,4] diazepine-1-one analogues S136313C NMR (100 MHz, CDCl3); 191.9, 159.6,157.5, 151.5, 142.1,
140.1, 131.0, 129.0, 126.5, 121.8, 117.5, 116.6, 114.9, 113.5,
106.6, 105.0, 101.1, 100.0, 55.3, 47.9, 29.4, 27.9, 25.0.
6.2.8. 8-chloro-7-(3,4-dichlorophenoxy)-11-(4-
methoxyphenyl)-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4] diazepin-1-one (4h)
White Solid, ES-MS m/z (%): 515 (M+H) 1H NMR
(400 MHz,CDCl3); 7.71–7.28 (m,3H), 7.12–6.87 (m,4H),
6.49–6.05 (m,2H), 5.00 (d,1H), 4.0 (s,1H), 4.0 (s,1H), 3.91
(s,3H), 2.94 (t,2H), 1.96 (t,2H), 1.67 (m,2H) 13C NMR
(100 MHz, CDCl3); 191.9, 158.6, 156.5, 144.1, 135.6, 133.2,
133.1, 131.0, 129.0, 128.5, 126.3, 125.1, 120.8, 117.1, 116.6,
114.9, 109.5, 101.1, 58.8, 53.0, 39.4, 27.6, 26.8.
6.2.9. 8-chloro-11-(4-chlorophenyl)-7-(3,4-dichlorophenoxy)-
3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4i)
Yellow Solid, ES-MS m/z (%): 549 (M+H) 1H NMR
(400 MHz, CDCl3); 8.71–7.28 (m,3H), 7.37–7.34 (m,4H),
6.49–6.05 (m,2H), 5.00 (d,1H), 4.9 (s,1H), 4.2 (s,1H), 2.29
(d2H), 1.88 (d,2H), 0.94 (s,3H), 0.91 (s,3H) 13C NMR
(100 MHz, CDCl3); 192.9, 151.5, 145.4, 141.1, 137.0, 126.0,
128.5, 126.1, 120.9, 116.6, 114.9, 109.5, 101.1, 53.0, 50.1,
42.8, 32.7, 27.9.
6.2.10. 8-chloro-7-(3,4-dichlorophenoxy)-11-(3,4-
dihydroxyphenyl)-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4j)
Yellowish brown Solid, ES-MS m/z (%): 517(M+H) 1H NMR
(400 MHz, CDCl3); 7.71–7.28 (m,3H), 6.80–6.62 (m,3H), 6.49–
6.05 (m,2H), 5.35 (s,1H), 5.35 (s,1H), 5.00 (d,1H), 4.7 (s,1H),
4.3 (s,1H), 3.97 (t,2H), 2.66 (t,2H), 1.97 (t,2H) 13C NMR
(100 MHz, CDCl3); 196.1, 157.5, 155.5, 148.1, 137.3, 133.1,
131.0, 126.5, 121.7, 121.0, 117.9, 115.8, 114.9, 111.0, 109.5,
101.1, 53.0, 36.9, 27.9, 24.0.
6.2.11. 8-chloro-7-(3,4-dichlorophenoxy)-11-(2,4-
dimethoxyphenyl)-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4k)
Brown Solid, ES-MS m/z (%): 573(M+H) 1H NMR
(400 MHz, CDCl3); 7.71–7.28 (m,3H), 7.01–6.43 (m,3H),
6.49–6.05 (m,2H), 5.00 (d,1H), 4.0 (s,1H), 4.0 (s,1H), 3.83
(s,3H), 3.83 (s,3H), 2.94 (t,2H), 1.96 (t,2H), 1.67 (t,2H), 0.89
(s,3H), 0.85 (s,3H) 13C NMR (100 MHz, CDCl3); 194.9,
159.6, 152.5, 147.1, 143.1, 139.7, 129.0, 126.5, 120.7, 116.6,
114.9, 113.5, 106.4, 105.0, 101.1, 100.0, 56.1, 50.1, 47.0, 42.0,
32.7, 31.2, 27.0.
6.2.12. 11-phenyl-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one (4l)
Pale Yellow Solid, ES-MS m/z (%): 291(M+H) 1H NMR
(400 MHz, CDCl3); 7.93–7.23 (m,5H), 7.85–6.51 (m,4H),5.45 (d,1H), 4.5 (s,1H), 4.1 (s,1H), 2.94 (t,2H), 2.26 (t,2H),
1.97 (m,2H) 13C NMR (100 MHz, CDCl3) 187.9, 143.3,
141.5, 133.2, 128.3, 126.2, 120.5, 116.5, 115.1, 101.1, 53.0,
39.0, 27.9, 22.6.
Acknowledgements
The authors thankful to Mrs. Fatima Raﬁq Zakaria Chairman
Maulana Azad Educational Trust and Dr. M.H.G. Dehghan,
Principal, Y.B. Chavan College of Pharmacy, Dr. Raﬁq Zaka-
ria Campus, Aurangabad 431 001 (M.S.), India for providing
the laboratory facility.
References
Ator, N.A., Grifﬁth, R.R., 1997. J. Pharmacol. Exp. Ther. 282, 1442.
Campos, A.H., Velarde, F.I., Montengro, Y.V., Castillo, R., 2002.
Chem. Pharm. Bull. 50, 649.
Falco, J.H., Lioveras, M., Buira, I., Teixido, J., Borrell, J.I., Mendez,
E., Terencio, J., Palomer, A., Guglietta, A., 2005. Eur. J. Med.
Chem. 40, 1179.
Johnston, G.A.R., 2005. Curr. Pharm. Des. 11, 1867.
Liegeois, J.F.F., Bruhwyler, J., Damas, J., Nguyen, T.P., Chleide,
E.M.G., Mercier, M.G.A., Rogister, F.A., Delarge, J.E., 1993. J.
Med. Chem. 36, 2107.
Liegeois, J.F.F., Bruhwyler, J., Rogister, F.A., Delarge, J.E., 1995.
Curr. Med. Chem. 1, 471.
Nabih, K., Baouid, A., Hasnaoui, A., Selkti, M., Compain, P., 2003.
New J. chem. 27, 1644.
Nash, J., Nutt, D., 2004. J. Psychiatry 3, 11.
Olsen, R.W., Sieghart, W., 2009. Neuropharmacology 56, 141.
Rudolph, U., Crestani, F., Benke, D., Brunig, I., Benson, J.A.,
Fritschy, J.M., Martin, J.R., Bluethmann, H., Mohler, H., 1999.
Nature 401, 796.
Rudolph, U., Crestani, F., Mohler, H., 2001. Trends Pharmacol. Sci.
22, 188.
Sangshetti, J.N., Chabukswar, A.R., Shinde, D.B., 2011a. Bioorg.
Med. Chem. Lett. 21, 444.
Sangshetti, J.N., Nagawade, R.R., Shinde, D.B., 2009. Bioorg. Med.
Chem. Lett. 19, 3564.
Sangshetti, J.N., Shinde, D.B., 2010a. Bioorg. Med. Chem. Lett. 20,
742.
Sangshetti, J.N., Shinde, D.B., 2011. Eur. J. Med. Chem. 46, 1040.
Sangshetti, J.N., Shinde, D.B., 2010b. Lett. Drug Des. Discovery 7,
171.
Sangshetti, J.N., Shinde, D.B., Sarkate, A.P., 2011b. Chem. Biol. Drug
Des. 78, 800.
Sheibani, H., Saida, K., Abbasnejad, M., Derakhshani, A., Moham-
madzadeh, I., 2011. Arabian J. Chem.
Sieghart, W., 2006. Adv. Pharmacol. 54, 231.
Susana, H., Isabel, M., Raul, S., Marı´a, T.H., Esther, D., 2011. Org.
Biomol. Chem. 9, 2251.
Tonkikh, N.N., Strakovs, A., Rizhanova, K.V., Petrova, M.V., 2004.
Chem. Heterocycl. Compd. 40, 949.
Wang, S.L., Chuang, C., Fei-yue, W., Rajale, T., 2011. Tetrahedron
67, 4485.
